Symbols

INCY

Incyte·NASDAQ

--(--)

INCY fundamentals

INCY Q4 2025 Earnings

Incyte (INCY) released its earnings on Feb 10, 2026: revenue was 1.51B (YoY +27.84%), beat estimates; EPS was 1.8 (YoY +26.24%), missed estimates.

Revenue / YoY

1.51B

+27.84%

EPS / YoY

1.8

+26.24%

Report date

Feb 10, 2026

INCY Earnings Call Summary for Q4,2025

Revenue Growth: 2025 total revenue $5.14 billion (+21% YoY), core business ex-Jakafi up 53% to $1.26 billion. 2026 guidance $4.77-4.94 billion, core business ex-Jakafi +30%.
Key Products:
- Jakafi: 2026 sales $3.22-3.27 billion, Jakafi XR launch mid-2026.
- Opzelura: 2026 sales $750-790 million, pediatric AD launch and international expansion.
- Hematology/Oncology: 2026 sales $800-880 million, driven by Monjuvi, Niktimvo, and Zynyz.
Pipeline Catalysts: 14 pivotal trials in 2026, including povorcitinib (HS/NV/vitiligo), tafasitamab (DLBCL), and KRAS G12D inhibitor for PDAC.
Financial Discipline: 2026 R&D/S&G expenses $3.495-3.675 billion (+4% YoY), with R&D up 10% for late-stage pipeline.

Earnings

EPS

Revenue

Revenue & Expenses

INCY has released its 2025 Q4 earnings report, with revenue of 1.51B, reflecting a YoY change of 27.84%, and net profit of 299.28M, showing a YoY change of 48.74%. The Sankey diagram below clearly presents INCY's revenue sources and cost distribution.

Key Indicators

Incyte (INCY) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Incyte (INCY)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Incyte (INCY)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Incyte (INCY)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown